bioAffinity
  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Select Page

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

by Dale Harrison | Jan 24, 2023 | Press Releases

Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity SAN ANTONIO, TX – Jan 24, 2023 – – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “Detection of early-stage...

Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning

by Dale Harrison | Jan 23, 2023 | Publications

Respiratory Research, January 21, 2023   Authors Lemieux, M.E., Reveles, X.T., Rebeles, J. et al. Abstract Background Low-dose spiral computed tomography (LDCT) may not lead to a clear treatment path when small to intermediate-sized lung nodules are identified....

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments

by Dale Harrison | Jan 4, 2023 | Press Releases

SAN ANTONIO, TX – Jan 4, 2023 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for...

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes

by Dale Harrison | Dec 28, 2022 | Articles, News

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes DECEMBER 28, 2022 As published in the The Fly By: Jessica de Sa-Mota BioAffinity focuses on the development of noninvasive, early-stage cancer diagnosis and targeted cancer treatment In an...

bioAffinity President & CEO to meet with institutional investors and bankers during J.P. Morgan Annual Healthcare Conference in San Francisco, January 9-12, 2023

by Dale Harrison | Dec 28, 2022 | Events

December 30, 2022 bioAffinity President & CEO Maria Zannes will meet with the institutional investors and investment banking groups while attending the WuXi Global Forum “Advancing Breakthroughs for Patients” during the J.P. Morgan 41st Annual Healthcare...
« Older Entries

Categories

  • Articles (15)
  • Events (34)
  • News (40)
  • Press Releases (56)
  • Publications (15)

Recent Posts

  • bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research January 24, 2023
  • Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning January 23, 2023
  • bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments January 4, 2023
  • Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes December 28, 2022
  • bioAffinity President & CEO to meet with institutional investors and bankers during J.P. Morgan Annual Healthcare Conference in San Francisco, January 9-12, 2023 December 28, 2022

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Copyright © 2023 bioAffinity Technologies, Inc.